Arrowhead Pharmaceuticals (ARWR) Depreciation & Amortization (CF) (2010 - 2026)

Arrowhead Pharmaceuticals (ARWR) has 17 years of Depreciation & Amortization (CF) data on file, last reported at $6.4 million in Q1 2026.

• Quarterly Depreciation & Amortization (CF) rose 4.67% year-over-year to $6.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $25.4 million (up 20.07% YoY) and the FY2025 annual result came in at $23.9 million, up 28.68% from the prior year.
• Depreciation & Amortization (CF) was little changed at $6.4 million in Q1 2026, from $6.4 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $6.4 million in Q4 2025 to a low of $2.6 million in Q1 2022.
• A 5-year average of $4.4 million and a median of $4.5 million in 2024 frame the typical range for Depreciation & Amortization (CF).
• Annual changes were most pronounced in 2023 — Depreciation & Amortization (CF) climbed 2.89% — and 2024, when it soared 69.54%.
• Tracing ARWR's Depreciation & Amortization (CF) over 5 years: stood at $2.7 million in 2022, then jumped by 58.53% to $4.3 million in 2023, then grew by 22.8% to $5.2 million in 2024, then gained by 22.06% to $6.4 million in 2025, then slipped by 0.34% to $6.4 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $6.4 million (Q1 2026), $6.4 million (Q4 2025), and $6.4 million (Q3 2025), per Business Quant data.